Access

Review

Nature Reviews Drug Discovery 4, 727–740 (1 September 2005) | doi:10.1038/nrd1824

Opportunities and Challenges in Antiparasitic Drug Discovery

Richard Pink , Alan Hudson , Marie-Annick Mouri|[egrave]|s & Mary Bendig

New antiparasitic drugs are urgently needed to treat and control diseases such as malaria, leishmaniasis, sleeping sickness and filariasis, which affect millions of people each year. However, because the majority of those infected live in countries in which the prospects of any financial return on investment are too low to support market-driven drug discovery and development, alternative approaches are needed. In this article, challenges and opportunities for antiparasitic drug discovery are considered, highlighting some of the progress that has been made in recent years, partly through scientific advances, but also by more effective partnership between the public and private sectors.